UTHouston nano pioneer test-launching multistage drug delivery system


This illustration shows the arrival of a nanocarrier and its payload of anti-cancer medication. (Illustration: Matthew Landry)

December 26, 2007 — Nanomedicine pioneer Mauro Ferrari and colleagues at The University of Texas Health Science Center at Houston have developed a new way to get intravenous agents for cancer and other diseases to the parts of the body where they’re needed most and to reduce the amount that goes to other areas where unintended injury can occur.

Their innovative nanoscale drug delivery system uses a multi-stage approach to guide nanocarriers that are about 100 times smaller than a strand of hair through the blood system and to the site of diseased cells where they release a payload of diagnostic agents or medications, or both.

“NanoMedicine is about getting the right amount of medication to the right location at the right time,” said Ferrari, who heads the 40-person NanoMedicine Research Center in the university’s Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), as well as the Alliance for NanoHealth, a consortium made up of UT-Houston and six other institutions.

Currently being tested on human tumors in animal models, the system developed in Ferrari’s IMM lab could allow physicians to get the same results with less medication. Only a tiny fraction of an injected drug now reaches its intended target. Too much medication can injure a patient; too little, and there are no therapeutic effects.

“The multi-stage approach to nano drug delivery will increase efficacy and reduce toxicity,” Ferrari said. “We hope to reduce systemic exposure which will allow current drugs to be more effective. Furthermore, newer drugs may have a better chance of coming to market because of reduced toxicity profiles.”

Getting these nanocarriers and their contents from the tip of a syringe to diseased cells is no easy task. The nanocarriers must avoid being corrupted by enzymes, swallowed up by the body’s immune system and trapped inside blood vessels.

“This is kind of like opening a door. You need to open all ten doors to get to the diseased cells. It’s not enough to open nine,” Ferrari said.

“The first stage goes to the inner wall of a blood vessel near the diseased cells. As the nanocarrier degrades, it releases the second stage – tiny nanoparticles that penetrate the walls of the inner blood vessels and enter the diseased cells. The third stage is then released and it consists of either the medication to kill the tumor cells or the contrasting agents to get quality medical images of it, or both” said Ennio Tasciotti, Ph.D., the senior postdoctoral researcher in Ferrari’s IMM lab.

The multi-stage system is composed of a biodegradable nanocarrier made of silicon that is fully biocompatible and thus does not injure the body. This first-stage cargo can be loaded with even smaller nanoparticles (up to 50 nanometers) that can in turn contain medications or contrast agents.

The nanocarriers are engineered to seek out blood vessels that sprout to support diseased cells, which differ from normal vessels. This is accomplished by coating the nanocarriers with targeting molecules that can recognize and latch onto the cells lining the inner walls of disease-associated blood vessels. Targeting molecules include antibodies, peptides, oligonucleotides and aptamers.

The nanocarriers have pores that expand as the nanocarrier degrades and allow the nanoparticles inside to escape, Tasciotti said. The nanoparticles then travel through the tiny holes in disease-associated blood vessels and into the targeted cells, where the therapeutic or imaging agents are released.

Supported with recently-awarded grants totaling $4.3 million from the National Cancer Institute (NCI) and three organizations in the U.S. Department of Defense, Ferrari’s IMM lab is working closely on the multi-stage project with scientists from the Alliance for NanoHealth.

Department of Defense and NCI officials are particularly interested in applying this emerging technology to breast cancer, which is the focus of the initial preclinical tests. Ferrari’s multi-stage drug delivery system is envisioned to be used one day in treating heart disease, hemorrhaging and other conditions with disease-associated changes in blood vessel arrangement.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

NEW PRODUCTS

Spectral reflectometer for film thickness measurement
04/08/2014Verity Instruments, Inc. is pleased to announce the availability of its new SP2100 Spectral Reflectometer designed for film thickness measurement f...
New Kimtech Pure G3 EvT nitrile gloves
04/03/2014Kimberly-Clark Professional has introduced a new glove that is designed to provide process protection for the semiconductor and electronics industries....
UVOTECH releases UV-Ozone Cleaning System
04/03/2014Using a UV-Ozone Cleaner, near atomically clean surfaces can be achieved in minutes without any damage to your devices. ...